Vote for Greg Lesinski @lesinskilab.bsky.social for SITC At-Large Director. An outstanding leader, mentor, collaborator, and innovator advancing cancer immunotherapy for patients. #SITC #CancerResearch @winshipcancer.emory.edu @cholangiocarcinoma.bsky.social

Society for Immunotherapy of Cancer@sitcancer.bsky.social · 3mo ago

Learn about 2026 SITC At-Large Director candidate, Gregory B. Lesinski, PhD, MPH (Winship Cancer Institute of Emory University). Read about Dr. Lesinski: https://www.sitcancer.org/get-involved/2026-sitc-election#lesinski

Check out our new research on developing a model for tumor infiltrating lymphocyte (TIL) therapy for cholangiocarcinoma (CCA) by the Lesinski and Paulos Labs! @lesinskilab.bsky.social @chrystalpaulos.bsky.social academic.oup.com/jimmunol/adv...

Development of a murine tumor-infiltrating lymphocyte therapy model for cholangiocarcinoma

Abstract. Tumor-infiltrating lymphocyte (TIL) therapy is a promising approach, earning U.S. Food and Drug Administration approval in patients with anti–PD-

academic.oup.com

The City of Atlanta is opening its first municipal grocery store today. The city is spending $3.5 million in partnership with a neighborhood grocery chain in an effort to eliminate a downtown food desert. www.wsbtv.com/news/local/a...

City of Atlanta opening grocery store to clear up downtown food desert

The Azalea Fresh Market opens on Friday.

wsbtv.com

www.v.org/grants/chrys... Honored to be awarded the All-Star V Foundation grant! Inspired by great team efforts between #Paulos and #Lesinski labs! Props to cell therapy gurus @megen-w.bsky.social #AnnaCole @meganmw.bsky.social and crew @winshipcancer.emory.edu

Chrystal Paulos, PhD - V Foundation

Melanoma is a serious and often deadly type of skin cancer. Although immunotherapy has saved many lives, it still doesn’t work for every patient. Our lab is developing ways to give the immune system a...

v.org

🧵1/ New in @Cancer_Cell: Our lab discovered that Th17 cells must team up with B cells to eliminate tumors, and prevent it from coming back. 🔗 Read: www.cell.com/cancer-cell/... 🧬This unexpected immune duo sparks tumor immunity. 🖼️Image: See schematic Th17/B cell antitumor action!

Adoptively transferred Th17 cells cooperate with host B cells to achieve durable tumor immunity

Cole et al. report that adoptively transferred, tumor-specific Th17 cells engage host B cells and drive B cell proliferation and differentiation. These Th17 cells require B cells for sustained immunit...

cell.com

Check out our new paper in Hepatology on how myeloid cells limit immunotherapy in preclinical cholangiocarcinoma models! Disease site matters! @chrystalpaulos.bsky.social @megen-w.bsky.social @winshipcancer.emory.edu many others! pubmed.ncbi.nlm.nih.gov/40590857/

Tumor site influences efficacy of MEKi and immunotherapy combinations in pre-clinical model of cholangiocarcinoma - PubMed

These findings identify myeloid cells as key mediators of both immunotherapy resistance and toxicity in CCA, highlighting the critical importance of tumor site and use of physiologically relevant pre-...

pubmed.ncbi.nlm.nih.gov

Amazing talk by Dr. Ayana Ruffin @winship on the importance of CD2 in adoptive immunotherapy of cancer. It’s a T:B thing. #2025SIS on the UVA campus.

Not a trend I will partake in. :/

The New York Times@nytimes.com · last yr.

The latest drinking craze? Dropping a few jalapeño slices into a chilled glass of white wine.

This week I will be attending the @helloeacr.bsky.social conference, entitled "Defense is the Best Attack," where we'll catch up on the latest advances in immuno-oncology and advanced therapies. It's always a great opportunity to meet people and learn from the best. Hoping to meet you all there! 😁🧪

Excited to present at the first Breast Center Translational Research Seminar Series @winshipcancer.emory.edu Thank Dr. Shipra Gandhi for the invite.

www.biorxiv.org/content/10.1...

A systematic approach to analyze T cell migration: application to mouse melanoma tumors

T cells must assess and choose between surveilling large areas, but also engage efficiently with the target cells. This process is translated into variations in speed and turning angle of T cells. In ...

biorxiv.org

www.biorxiv.org/content/10.1...

An Aged Microenvironment Increases CAR T Cell Cytotoxicity but Impairs Therapeutic Efficacy

Background Cancer disproportionately affects the elderly, who are often less able to tolerate traditional cytotoxic therapies, and may benefit from T cell–based immunotherapies. However, studies evalu...

biorxiv.org

pubmed.ncbi.nlm.nih.gov/39585339/

Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma - PubMed

Response-adaptive surgical timing enhanced treatment response. IDOi BMS986205 augmented pTR in patients with high IDO1 expression in baseline samples, indicating a need for identifying and targeting r...

pubmed.ncbi.nlm.nih.gov

What is the most important unanswered questions to address in the field of cancer immunotherapy?

Delighted to present our labs exciting work on T cell metabolism and cancer immunotherapy today at AACR by Guillermo Rangel Rivera and Soundharya Kumaresan!

Our findings highlight the critical role of T cell trafficking to the lymph nodes in shaping neoantigen-specific antitumor responses and offers insight for improving adoptive cellular therapies www.biorxiv.org/content/10.1...

Neoantigens drive adoptively transferred CD8 T cells to long-lived effectors mediated by lymph node trafficking

Adoptive transfer of neoantigen-reactive T lymphocytes mediates potent responses against solid tumors in patients while often limiting toxicity to normal tissues; however, the mechanisms governing the...

biorxiv.org

Check out this awesome body of elegant work by @lesinskilab.bsky.social @winshipatemory.bsky.social on the immune landscape of primary vs metastatic tumor of patients with pancreatic cancer. Must read!!!!

LesinskiLab@lesinskilab.bsky.social · last yr.

www.biorxiv.org/content/10.1... Excited to share our preprint on comparing Human Primary and metastatic #pancreaticcancer!!!

Stellar team!!

LesinskiLab@lesinskilab.bsky.social · last yr.

So very proud of our newly minted Dr. Maggie Phillips! @winshipatemory.bsky.social She showcased her amazing translational oncology experience in today’s public defense!

Inspiring (as always) @cholangiocarcinoma.bsky.social annual meeting comes to a close. Our @winshipatemory.bsky.social team returns motivated by survivors, patients and caregivers to make a difference! @megen-w.bsky.social @chrystalpaulos.bsky.social

Excited to present our labs work on novel T cell therapies @clevelandclinic.bsky.social virtually @winshipatemory.bsky.social Thank you for the invite #LilyWang!

💥Cheers to Megen Wittling @megen-w.bsky.social @winshipatemory.bsky.social for presenting exciting work on the distinct trafficking & activation patterns of adoptively transferred CD8 T cells that recognize non-mutated va mutated tumors.

Going to talk about antitumorT cell prowess at KUMC today. Thanks to Dr. Kalyani Pyaram for inviting me to visit and talk about our labs work @winshipatemory.bsky.social

A study in Nature Immunology finds that a single injection of CAR T cells, designed to target drivers of allergic reactions, represses the signs and symptoms of allergic asthma in mice for at least a year. go.nature.com/3VeWuVg 🧪

#CUAnschutz researchers have developed a supercharged iteration of CAR-T cell therapy that can enhance the effectiveness and longevity of the cells, particularly against #cancer cells that are harder for prior CAR-T therapies to detect and fight. 🗞️⬇️

New CAR-T Cell Therapy Shows Promise for Hard-to-Treat Cancers

New CAR-T Cell Therapy Shows Promise for Hard-to-Treat Cancers

news.cuanschutz.edu

From 2010 to 2016 (latest data I have ), NIH research contributed to EVERY drug approved by the FDA

Delighted to present at the MD Anderson annual retreat this year in Galveston Texas.

We survived the Spartan Trial Run!

3 points of progress vs pancreatic cancer! 1. Neoantigen vaccines www.nature.com/articles/s41... 2. KRAS drugs www.wsj.com/health/healt... 3. Early diagnosis www.science.org/doi/10.1126/...